Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Stephen M. DeMoss who wrote (3549)	12/18/1999 11:59:00 AM
From: Kevin Podsiadlik	Read Replies (2) \| Respond to of 4140

One thing you kind of gloss over ("...some sort of approval.") is that there are possible outcomes other than just thumbs-up or thumbs-down. There could also be approval with conditions, which could be a lot of things, but one of the more likely being that the product be labelled as being a "temporary" measure. Actually, this last scenario is probably best for all involved, as it will give those who are long a chance to sell to those who fail to read anything other than the word "approval", and those who are short will cash in when the analysts step in and carefully explain that, despite anything Trenary might have implied, people will take into account the magnitude and persistence of a prospective eye treatment before laying down big money for it. In theory, we could see both $30 AND $5 the next morning in that case.